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The mainstay treatment of non alcoholic fatty liver disease (NAFLD) based on weight loss and/or lifestyle changes is
most often unsuccessful at all ages, thus requiring the implementation of pharmacological strategies. Targeting
insulin resistance and oxidative stress has recently proven unsatisfactory. Among a number of proposed innovative
approaches targeting novel pathomechanisms, probiotics appear an interesting and reasonable option acting on
gut-liver axis malfunction through the modulation of diet-driven, obesogenic, and inflammatory intestinal
microbiota.
A combined multiple pharmacological therapy directed simultaneously towards novel and old pathomechanisms
(including, e.g., insulin resistance, oxidative stress, gut-liver axis, apoptosis) along with lifestyle interventions however
might be necessary both in adult and pediatric NAFLD therapy.
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The available treatment options for NAFLD at all ages
are currently still far from being satisfactory. Therefore
we read with much interest the article by Giorgio et al.
which appeared most recently in the Journal [1]. The
Authors gave pediatricians a thorough update on several
aspects of NAFLD pathomechanisms, which were
reviewed also under the light of potential treatments
targets. Dr Giorgio et al. should be congratulated in par-
ticular for the attention paid also to the intestinal micro-
biota and the gut-liver axis. These issues in fact only
recently emerged as additional, possibly pivotal, protago-
nists in the busy scenario of NAFLD pathogenesis not
only in animal models [2] but also in humans, including
childhood [3]. This now begins to appear paramount
due to intestinal microbiota’s susceptibility of being
modulated by a number of agents (including pre-, pro-,
and syn-biotics) [4].
Since the 2007 Cochrane meta-analysis [5], which
could neither suggest nor refute the use of probiotics as
therapeutic option for patients with NAFLD and non-
alcoholic steatohepatitis (NASH), most recently at least
two double blind, controlled, pilot RCTs (both with* Correspondence: pvajro@unisa.it
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reproduction in any medium, provided the orprobiotics as the sole treatment) became available in the
literature [6,7]. Both studies showed encouraging prelim-
inary good results upon aminotransferases activity in
adults [6] and, even more, in pediatric population where
also a number of markers of intestinal dysbiosis and/or
gut-liver axis malfunction appeared to be modulated by
probiotic treatment [7]. Hence, these results, altogether,
appear to nicely fit the intense network existing between
gut and liver and probiotics influence [3,4] which also
Giorgio et al. mentioned in their study [1]. Moreover
they may add further strength to the Authors’ view that
large, well conducted, controlled studies with probiotics
or other therapeutic tools able to interact with the gut
microbiota, alone and/or together with other thera-
peutic measures (i.e. “multi-target therapy” avoiding
the monotherapeutic direction approach) [4,8], appear
fully justified also in pediatric NAFLD.
At the same time, for future NAFLD therapeutic studies,
one should underline the importance of warning on the
strict monitoring patients’ anthropometric changes to
avoid under/over-estimation of the effects of the therapies
under consideration. Unpredictable concurrent individual
lifestyle changes in fact represent a relevant confounding
factor which has hitherto flawed a number of medium
and long-term studies in both pediatric and adult obese
populations [4]. Accordingly, also the categorical needd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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follow-up histological liver damage should be cautiously
reconsidered. In addition to the unpredictability of sam-
pling error potentials, one should bear in mind that
liver biopsy results may in fact represent only a transi-
ent & mutable snapshot during the extremely irregular
lifestyle- and diet-driven hepatic histological changes,
especially in the pediatric age.
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